Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 5, 2007, Pages 595-596

  Sungkanuparph, Somnuek ^a   Jongwutiwes, Ubonvan ^b   Kiertiburanakul, Sasisopin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE DISTRIBUTION; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCAL MENINGITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; KAPLAN MEIER METHOD; LETTER; PRIORITY JOURNAL; PROPHYLAXIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX RATIO; VIRUS CULTURE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CRYPTOCOCCUS; FEMALE; HUMANS; INFLAMMATION; KAPLAN-MEIERS ESTIMATE; MALE; MENINGITIS, CRYPTOCOCCAL; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548081385     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318061b5eb     Document Type: Letter

References (14)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18:1615-1627.
3. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000;1:107-115.
4. Hirsch HH, Kaufmann G, Sendi P, et al. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004;38:1159-1166.
5. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. 1998;351:252-255.
6. Michelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS. 1998;12:1815-1822.
7. Cheng VC, Yuen KY, Chan WM, et al. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis. 2000;30:882-892.
8. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis. 2002;35:e128-e133.
9. Lortholarya O, Fontanetb A, Me'maind N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005;19:1043-1049.
10. Shelburne SA III, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:1049-1052.
11. Cheng VC, Yuen KY, Chan WM, et al. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis. 2000;30:882-892.
12. Cooney EL. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin Infect Dis. 2002;34:224-233.
13. Skiesta DJ, Hesterb LJ, Hardya RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect. 2005;51:e289-e297.
14. Zhou J, Ditangco R. Predict immune reconstitution syndrome. Clin Infect Dis. 2006;43:147-148.